natgillin/translations-raw huggingface dataset:
A use in accordance with para 30, wherein the GPR119 agonist and the DPP-IV inhibitor are provided in amounts sufficient to lower a blood glucose level. 
GPR119. Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je oralno aktivan,
Vaccine according to embodiment 16, wherein the protein carrier is selected from the group consisting of keyhole limpet haemocyanin (KLH), tetanus toxoid (TT), protein D or diphtheria toxin (DT), preferably a mutated diphtheria toxin, more preferably CRM197. 
Cjepivo prema zahtjevu 3, naznačeno time, da je proteinski nosač odabran iz skupine koja se sastoji od Keyhole Limpet hemocijanina (KLH), tetanus toksoida (TT), proteina D ili difterijskog toksina (DT), poželjno mutiranog toksina difterije, a još poželjnije CRM197.
The compound of claim 1 wherein (A) is phenyl, pyridinyl, thiophenyl, pyrrolyl, furanyl, or thiazolyl, and further wherein (A) has n substituents (R3). 
Spoj prema zahtjevu 1, naznačen time, da (A) je fenil, piridinil, tiofenil, pirolil, furanil, ili tiazolil, i nadalje time, da (A) ima n supstituenata (R3).
Identification assembly according to claim 1 or 2, wherein the substrate (12) comprising plastic material, such as polycarbonate. 
Sklop za identifikaciju prema patentnom zahtjevu 1 ili 2, pri čemu se supstrat (12) sastoji od plastičnog materijala kao npr. polikarbonata.
Once testing is completed, the work memory area is copied in the tested second bank, work operations are performed on the second bank, and the first bank is tested. 
Nakon što je testiranje dovršeno, područje radne memorije se kopira u testiranu drugu banku, radne se operacije izvode na drugoj banci, a prva se banka testira.
A pharmaceutical aerosol formulation for use in pressurized metered dose inhalers comprising: 
Farmaceutska aerosolna formulacija za upotrebu u inhalatorima sa stlačenim inhalatom koja sadrži sljedeće:
The mixture was heated to 80°C under reflux for 3 hours. 
Smjesa je zagrijana do 80 "C uz refluksiranje tijekom 3 sata.
A-B-A (I) or (A-B)nX (II) wherein each block A represents a polymeric block obtained from vinyl aromatic monomers; each block B represents a polymeric block obtained from monomers of conjugated dienes; X represents a radical deriving from a coupling agent; n is an integer ranging from 2 to 30, preferably from 3 to 10. 
(1) ili (A-B),X (ID) gdje svaki blok A predstavlja polimerni blok dobiven iz viniliranih aromatskih monomera; svaki blok B predstavlja polimerni blok dobiven iz monomera konjugiranih diena; X predstavlja radikal izveden iz kopulacijskog sredstva; n je cijeli broj u rasponu od 2 do 30.
An antisense oligonucleotide according to claim 5, wherein the nucleotide analogue has a modified base. 
Besmisleni oligonukleotid u skladu s patentnim zahtjevom 4, pri čemu analog nukleotida ima modificiranu bazu ifili modificiranu unutarnukleozidnu vezu.
NO:16 and a light chain comprising the sequence given in SEQ ID NO:18 to which PEG, preferably PEG-maleimide, is covalently linked to the interchain cysteine of CL and the interchain cysteine of CH1. 
Neutralizirajuće antitijelo koje ima specifičnost za ljudski IL-17, naznačeno time da ima teški lanac koji sadrži sekvencu prikazanu u SEQ ID NO:16 i laki lanac koji sadrži sekvencu prikazanu u SEQ ID NO:18 1 na koje su vezane dvije efektorske molekule.
The pharmaceutical composition according to claim 14 in solid, semi-solid, pasty or liquid form. 
Farmaceutski pripravak prema patentnom zahtjevu 1 u čvrstom, polu-čvrstom obliku ili obliku paste.
wherein the intracellular portion of the rodent CD47 polypeptide is encoded by the exons downstream of exon 7 of a rodent CD47 gene; and wherein the humanized CD47 gene is operably linked to a rodent CD47 promoter. The rodent of claim 1, wherein the humanized CD47 gene is formed from a replacement of a genomic fragment comprising exons 2-7 of an endogenous rodent CD47 gene at an endogenous rodent CD47 locus, with a genomic fragment comprising exons 2-7 of the human CD47 gene. 
Glodavac čiji genom sadrži humanizirani gen CD47, naznačen time što humanizirani gen CD47 sadrži egzon 1 iz endogenog glodavačkog gena CD47, egzone 2-7 iz ljudskog gena CD47, te egzone nizvodno od egzona 7 iz endogenog glodavačkog gena CD47, gdje je humanizirani gen CD47 operabilno spojen s promotorom endogenog glodavčkog CD47.
A kit comprising a conjugated nucleic acid molecule according to any one of claims 1 to 3 and a DNA-damaging anti-tumoral agent, as a combined preparation for simultaneous, separate or sequential use. 
Komplet, naznačen time što sadrži konjugiranu molekulu nukleinske kiseline u skladu s patentnim zahtjevom 2 ili 4 i protutumorsko sredstvo koje oštećuje DNA, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu.
The method of claim 11, wherein the at least one other therapeutic agent includes a therapeutic agent selected from imiglucerase and 1,5-(butylimino)-1,5-dideoxy-D-glucitol. 
8. Spoj za uporabu prema zahtjevu 7, naznačen time što je barem jedno drugo terapeutsko sredstvo imigluceraza ili 1,5-(butilimino)-1,5-dideoksi-D-glucitol.
The compound of claim 1, which is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj: O
A dietary composition comprising an oil composition according to claim 6. 
Dijetetski sastav koji sadrži sastav ulja sukladno zahtjevu 6.
A pharmaceutical composition comprising the oligomeric compound of any one of the preceding embodiments, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant. 
Farmaceutski pripravak, naznačen time, da obuhvaća oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 16 1 farmaceutski prihvatljivo sredstvo za razrjeđivanje, nosač, sol ili adjuvant.
No. 4,018,830 and U.S. Pat. No. 4,055,665 discloses “phenylthioaralkylamines” and “2-phenylthiobenzylamines” represented structurally as “Ar1-S-Ar2 in which Ar1 is a phenylakyl amine substituent and Ar2 is a substituted or unsubstituted homocyclic or heterocyclic ring of from 5-6 atoms, such as an aromatic ring, a heteroaromatic ring”. 
US 4,018,830 i US 4,055,665 opisuju "feniltioaralalkilamine" i "2-feniltiobenzilamine" koji su strukturalno predstavljeni kao "Ar;,-S-Ar»" u kojem je Ar, fenilakil amin supstituent, a Ar, je supstituirani ili nesupstituirani homociklični ili heterociklični prsten 5-6 atoma, kao što je to aromatični prsten, heteroaromatični prsten".
The iron-fortified food stuff according to claim 2, wherein the at least one bioavailable iron salt is ferric saccharate. 
Živežna namirnica obogaćena željezom u skladu s patentnim zahtjevom 2, naznačena time što je najmanje jedna biodostupna željezna sol feri saharat.
The process according to claim 13, wherein the [2-(acylaminoethyl)thio]arene compound has the formula and is reacted with the formaldehyde and an acid to form a protected benzothiazepine of the formula: or 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da [2-(acilaminoetil) tio]arenski spoj ima formulu [image] i izlaže se reakciji s formaldehidom i kiselinom, čime se dobiva zaštićeni benzotiazepin formule:
Wind system (1) according to claim 2, characterised in that said trolley (11) is equipped with said wheels (16, 17) to support said trolley (11) weight. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da spomenuta opruga bude pritisnuta zbog djelovanja napetosti spomenutog užeta (4).
The system of claim 6 wherein a DC power source is configured to provide the spinal direct current in a range from about 2 mA to about 5 mA for treatment of disability in humans. 
Sustav sukladno zahtjevu 1 pri čemu je navedena istosmjerna struja za spinalnu stimulaciju opsega od otprilke 2 ma do otprilike 5mA za terapiju mišićnog tonusa kod ljudi.
A method of purifying a monomeric platinum pyrophosphate complex of formula (I) or formula (II): or a salt thereof, comprising: dissolving the monomeric platinum pyrophosphate complex in a buffer having a pH in the range of 6 to 9 and comprising a pyrophosphate salt; recrystallizing the complex from the buffer; isolating the monomeric platinum pyrophosphate complex; and washing and drying the isolated monomeric platinum pyrophosphate complex, wherein R1 and R2 are each independently NH3, an aliphatic amine, or an aromatic amine; and wherein R3 is an aliphatic diamine or an aromatic diamine. 
Postupak za dobivanje monomernog kompleksa platina pirofosfata, ili njegove soli, naznačen time da sadrži: miješanje spoja platina dihalogenida sa soli pirofosfata u sustavu otapala koje sadrži vodu i barem jedno organsko otapalo koje se miješa s vodom, održavanje reakcijske smjese pri čemu spoj platina dihalogenid reagira sa soli pirofosfata tako da tvori monomerni kompleks platina pirofosfata; taloženje monomernog kompleksa platina pirofosfata; te izoliranje monomernog kompleksa platine iz reakcijske smjese.
A compound according to claim 1 for use in the treatment of conditions or disorders mediated by S1P1 receptors, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju stanja ili poremećaja povezanih s receptorima SIPI1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
Use of the composition according to anyone of claims 1-10 for the manufacture of a food composition or dietary composition for reducing the risk of alcohol induced cancer, neuropathy, a neurodegenerative disease, hangover syndrome, flushing syndrome, headache and/or intoxication by acetaldehyde. 
Uporaba pripravka prema bilo kojem od zahtjeva 1-10 naznačena time da je za proizvodnju prehrambenog pripravka ili dijetetskog pripravka za smanjivanje rizika od raka uzrokovanog alkoholom, neuropatije, neurodegenerativne bolesti, sindroma mamurnosti, flush sindroma, glavobolje i/ili trovanja sa acetaldehidom.
is phenyl, wherein said phenyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being halogen, (C1-C3)alkyl or (C1-C3)alkoxy; 
je fenil, pri čemu je spomenuti fenil nesupstituiran ili supstituiran s 1 ili 2 supstituenta koji su zasebno halogen, (C1-C3)alkil ili (C1-C3)alkoksi;
The composition for use according to claim 5, further comprising an anti-inflammatory agent selected from the group consisting ofNSAIDs, PPAR agonists, combinations thereof, and mixtures thereof. 
Pripravak za uporabu prema patentnom zahtjevu 5, naznačen time da nadalje sadrži anti-upalni agens izabran iz skupine koja se sastoji od NSAID-a, PPAR agonista, njihovih kombinacija, ili njihovih smjesa.
A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. A compound of formula I(a): 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1 1 farmaceutski prihvatljiv nosač.
Payment authorization method according to claim 17, wherein at step B the Intermediary electronic equipment obtains said authentication key from the Payer electronic equipment, said authentication key being a financial transaction code unique to the Payer. 
Postupak autorizacije plaćanja sukladno Zahtjevu 17, pri čemu u koraku B elektronička oprema Posrednika pribavlja navedeni autentifikacijski kod od elektroničke opreme Platitelja, navedeni autentifikacijski kod je kod financijske transakcije jedinstven za Platitelja.
wherein the second side of the rod is flush with the rear surface of the body. The cutting tool according to claim 1, wherein each of the first and second major lateral cutting edges is in the form of a smooth, undulated or jagged cutting edge, and the minor cutting edge is in the form of a jagged cutting edge. 
Alat u skladu s patentnim zahtjevom 1, naznačen time, da tijelo (2) ima u biti ravni i pravokutni oblik, sa dva glavna bočna ruba u obliku glatke oštrice, a donji rub nasuprot prvom kraju (31) šipke (3) ima oblik nazubljenog reznog ruba.
The method of claim 1, wherein the paroxetine hydrochloride is in a crystalline form. 
2. - Paroksetin za upotrebu prema patentnom zahtjevu 1, naznačen time što je paroksetin u kristalnom obliku.
Preferably the area of the spot is greater than the area of the puncture hole, e.g. at least 1.5 times greater, preferably at least 2 times greater, more preferably 3 or more times greater. 
Poželjno je da je veličina mrlje veća od veličine izbušene rupice, na primjer, najmanje 1.5 puta veća, poželjno najmanje 2 puta veća, još poželjnije 3 ili više puta veća.
The probiotic formulation of claim 7, wherein the ingestible carrier is a capsule, tablet, powder or a food product; optionally the food product is a dairy product, acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spread, dressing or beverage. 
Formulacija probiotika za uporabu iz patentnog zahtjeva 4 ili 5, pri čemu je jestivi nosač kapsula, tableta, prah ili prehrambeni proizvod. Formulacija probiotika za uporabu iz patentnog zahtjeva 6, pri čemu je prehrambeni proizvod mliječni proizvod, kiselo mlijeko, jogurt, zamrznuti jogurt, mlijeko u prahu, koncentrat mlijeka, sirni namaz, preljev ili napitak.
EYFP, a cysteine-containing peptide for ligation of a biarsenical dye or for conjugating metastable technetium, 
(i) peptida koji sadrži cistein za ligaciju biarseničke boje ili za konjugiranje metastabilnog tehnecija,
A cement admixture as recited in claim 4, wherein said calcium ferroaluminate and said potentially hydraulic substance and/or said pozzolan substance are blended together in a blending proportion of 10/1 to 1/10 by mass. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što se navedeni kalcijev feroaluminat i navedenu potencijalno hidrauličnu tvar i/ili navedenu pucolansku tvar pomiješa zajedno u omjeru miješanja od 10/1 do 1/10, maseno.
an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 221; and 
(11)protutijelo koje sadržava varijabilnu regiju teškog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 217 (H98) 1 varijabilnu regiju lakog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 221 (L50) (H98L50); 1
Core-(-L-NHE)n (X) or pharmaceutically acceptable salt thereof, wherein: 
Spoj za uporabu sukladno zahtjevu 3, pri čemu je farmaceutski prihvatljiva sol
In a class of this embodiment, in step 1), a temperature of the exhaust gas from the electric power plant is between 110 and 140° C.; a temperature of the exhaust gas after the first indirect heat exchange in the first heat exchanger is between 80 and 90° C.; and a temperature of the hot air provided for the vegetable greenhouse and/or algae culturing house is between 40 and 50° C. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je u koraku 1), temperatura ispušnog plina iz elektrane između 110 1 140*C; temperatura ispušnog plina nakon prve neizravne izmjene topline u prvom izmjenjivaču topline je između 80 i 90%C; i temperatura zagrijanog zraka predviđenog za staklenik povrća i/ili kuću za uzgoj algi je između 40 1 50*C.
The crude product was purified by flash chromatography on silica using a gradient of ethyl acetate/heptane (10:90 to 70:30) as eluent. 
Sirovi produkt se pročišćava sa brzom kromatografijom na silika gelu uz korištenje gradijenta etil acetat/heptan (10:90 do 70:30) za ispiranje.
Also within the scope of the invention is the use of any compound of the invention for the manufacture of a medicament for the therapy of Parkinson's disease. Also within the scope of the invention is the use of any of the compounds of the present invention, for the manufacture of a medicament for the treatment of any of the conditions discussed above. 
Uporaba spoja prema zahtjevu 1, naznačena time da je za proizvodnju lijeka za liječenje tjeskobe. Uporaba spoja prema zahtjevu 1, naznačena time da je za proizvodnju lijeka za liječenje depresije. Spoj prema zahtjevu 1, naznačen time da je za uporabu kod liječenja bola.
The nonwoven wipe according to claim 1, wherein the unbonded portions occupy more than about six times as much space as the bonded portions in the plan view of the area of the face of the nonwoven wipe. 
Netkani materijal prema zahtjevu 1, naznačen time da nespojeni dijelovi zauzimaju oko šest puta više prostora nego spojeni dijelovi u području lica netkanog materijala.
a′)—Moving the milling machine to a place of use specified in advance; 
a ́) - premještanje glodalice (100a-100e) na unaprijed određeno radno mjesto (EO, EO1);
R8b is independently selected from H and F; R8c is independently selected from H, F, Cl, and OCH3; and n, at each occurrence, is an integer independently selected from 0, 1, and 2. 
b je nezavisno izabran od H i F; c je nezavisno izabran od H, F, Cl, i OCH3; i n, pri svakom pojavljivanju, je cijeli broj nezavisno izabran od 0, 1, i 2.
A CAR according to any one of claims 11 to 17 wherein the costimulatory domain comprises a costimulating domain from any one or more of CD28, CD137 (4-1BB), CD134 (OX40), DapIO, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 and combinations thereof. 
CAR prema bilo kojem od patentnih zahtjeva 11 do 17 naznačen time što kostimulacijska domena obuhvaća kostimulacijsku domenu od bilo kojeg ili više CD28, CD137 (4-1BB), CD134 (OX40), DaplIO, CD27, CD2, CDS5, ICAM-I, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 i njihove kombinacije.
A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1): (wherein G is GlcNAc-Gal- or GlcNAc-) or a cyclodextrin inclusion compound thereof, and 
Protutumorsko kemoterapijsko sredstvo, naznačeno time, da sadrži, u kombinaciji, derivat kolestanola, prikazan formulom (1): [image] (pri čemu G predstavlja GlcNAc- ili GlcNAc-Gal-) ili njihov inkluzijski spoj ciklodekstrina, i irinotekan kao protutumorsko sredstvo.
Emb-3: The use according to Emb-1 or Emb-2, where the medicament further comprises at least one administration unit C containing dose c of tapentadol, where dose b < dose c. 
Tapentadol prema bilo kojem prethodnom patentnom zahtjevu, naznačen time da se doza c tapentadola daje tijekom trećeg intervala davanja, nakon drugog intervala davanja, gdje je doza b < doze c.
A medicament comprising a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof for the prophylaxis or treatment of nerve degeneration diseases. 
CH3CH2O-€ N (I) HR P20090593 TI gdje R! je kao definiran u zahtjevu 1, ili njegovu sol za profilaksu ili liječenje degeneracijskih oboljenja živaca. t>&
An antibody or antigen-binding fragment thereof that specifically binds human interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) for use in a method of treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of lung disorders, inflammatory disorders and allergic reactions, wherein the antibody or fragment thereof comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NO:148, 150 and 152, respectively, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NO:156, 158 and 160, respectively. 
Antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično vezuje za humani interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) za primjenu u metodi liječenja oboljenja ili poremećaja, naznačena time, što je oboljenje ili poremećaj odabran iz skupine koja se sastoji od oboljenja pluća, upalnih poremećaja 1 alergijskih reakcija, pri čemu antitijelo ili njegov fragment sadrži tri sekvence regije koja određuje komplementarnost teškog lanca (HCDR) koje sadrže SEQ ID NO:148 odnosno 150 odnosno 152 te tri sekvence regije koja određuje komplementarnost teškog lanca (LCDR) koje sadrže SEQ ID NO:156 odnosno 158 odnosno 160.
Example 8: Preparation of donepezil hydrochloride form I g donepezil base were suspended in methanol (300 ml) at room temperature and heated to 60°C to get a clear solution. 
Primjer 8: Priprema donepezil hidroklorida oblika I 50,6 g donepezilne baze suspendirano je u metanolu (300 mL) na sobnoj temperaturi i zagrijavano do 60 *C s ciljem dobivanja bistre otopine.
A pharmaceutical composition for use according to claim 5 wherein the conjugate comprises TNFa or TNFB linked to the targeting peptide CNGRC through the spacer G. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što konjugat sadrži TNFa ili TNFB vezan na ciljni peptid CNGRC preko razmaknice G.
the second fragment is a toxin B repeating domain fragment; 
(ii) drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
An angiotensin II receptor 1 (AT-1) antagonist in a therapeutically effective amount for use in the treatment of chronic kidney disease in cats, wherein such angiotensin II receptor 1 (AT-1) antagonist is a sartan. 
Antagonist receptora 1 (AT-1) angiotenzina Il, naznačen time, da se upotrebljava u terapeutski djelotvornoj količini za liječenje kroničnih bolesti bubrega kod mačaka, pri čemu takav antagonist receptora 1 (AT-1) angiotenzina II je sartan.
We set out below aspects of the invention: 
Datum objave europskog patenta:
The pharmaceutical composition according to claim 1 characterized in that at least 20% of the valsartan particles have a diameter in the range of 0.02 to 50 µm. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da najmanje 20 % čestica valsartana ima promjer u rasponu od 0,02 do 50 pm.
the provision of a core element, the covering of this core element with a strip of impregnable flexible material which continues transversely to the longitudinal direction of the core element to beyond this core element, 
- > prekrivanje ovog središnjeg elementa (1) trakom od fleksibilnog materijala koji se može impregnirati (2) i koji se postavlja poprijeko na uzdužni smjer središnjeg elementa (1) i nastavlja se prema van preko tog središnjeg elementa (1),
The biomaterial as claimed in claim 1, 4 or 5, wherein the ACP:HBC weight ratio is 25:75. 
Biomaterijali dobiveni kako je prijavljeno u patentnom zahtjevu 6, naznačeni time da omjer ACP:HBC jest 25:75.
The term “straight or branched C1-C5 sulfinyl” and “straight or branched C1-C5 thionyl” refers to a RS(═O)— moiety wherein R is selected from a straight or branched C1-C10 alkyl, straight or branched C2-C10 alkenyl and straight or branched C2-C10 alkynyl. 
alkenil, ravan ili razgranati C1-C5 alkinil, amin, ravan ili razgranati C1-C5 alkoksi, ravan ili razgranati C1-C5 karboksil, ravan ili razgranati C1-C5 ester, ravan ili razgranati C1-C5 tioksi, ravan ili razgranati C1-C5 sulfinil i ravan ili razgranati C1-C5 tionil;
forming a stack of gloves (106) according to the method of any one of Claims 7 to 10; 
- < oblikovanje snopa rukavica (106) prema postupku iz bilo kojeg od patentnih zahtjeva 7 do 10;